Literature DB >> 33388741

Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults.

Kailey Hughes1, Donald B Middleton1,2, Mary Patricia Nowalk2, Goundappa K Balasubramani2, Emily T Martin3, Manjusha Gaglani4, H Keipp Talbot5, Manish M Patel6, Jill M Ferdinands6, Richard K Zimmerman1,2, Fernanda P Silveira1,2.   

Abstract

BACKGROUND: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the nonimmunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults.
METHODS: We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using prespecified case definitions using electronic medical record data. VE was evaluated with a test-negative case-control design using multivariable logistic regression with polymerase chain reaction-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations.
RESULTS: Of 3524 adults hospitalized with ARI, 1210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%) and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years of age). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% confidence interval [CI], 21-44). VE among IC vs non-IC adults was lower at 5% (95% CI, -29% to 31%) vs 41% (95% CI, 27-52) (P < .05 for interaction term).
CONCLUSIONS: VE in 1 influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immunocompromised; influenza; vaccine; vaccine effectiveness

Mesh:

Substances:

Year:  2021        PMID: 33388741      PMCID: PMC8664442          DOI: 10.1093/cid/ciaa1927

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

2.  Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada.

Authors:  Phillip S Blanchette; Hannah Chung; Kathleen I Pritchard; Craig C Earle; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; James D McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew Simor; Marek Smieja; George Zahariadis; Aaron Campigotto; Jeffrey C Kwong
Journal:  J Clin Oncol       Date:  2019-08-29       Impact factor: 44.544

Review 3.  Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology.

Authors:  Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Jonathan S Nguyen-Van-Tam
Journal:  J Infect Dis       Date:  2012-08-16       Impact factor: 5.226

4.  The case test-negative design for studies of the effectiveness of influenza vaccine.

Authors:  Ivo M Foppa; Michael Haber; Jill M Ferdinands; David K Shay
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

5.  Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network).

Authors:  Michaela K Nichols; Melissa K Andrew; Todd F Hatchette; Ardith Ambrose; Guy Boivin; William Bowie; Ayman Chit; Gael Dos Santos; May ElSherif; Karen Green; Francois Haguinet; Scott A Halperin; Barbara Ibarguchi; Jennie Johnstone; Kevin Katz; Phillipe Lagacé-Wiens; Joanne M Langley; Jason LeBlanc; Mark Loeb; Donna MacKinnon-Cameron; Anne McCarthy; Janet E McElhaney; Allison McGeer; Andre Poirier; Jeff Powis; David Richardson; Anne Schuind; Makeda Semret; Vivek Shinde; Stephanie Smith; Daniel Smyth; Grant Stiver; Geoffrey Taylor; Sylvie Trottier; Louis Valiquette; Duncan Webster; Lingyun Ye; Shelly A McNeil
Journal:  Vaccine       Date:  2018-03-13       Impact factor: 3.641

6.  Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season.

Authors:  Min Z Levine; Emily T Martin; Joshua G Petrie; Adam S Lauring; Crystal Holiday; Stacie Jefferson; William J Fitzsimmons; Emileigh Johnson; Jill M Ferdinands; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 5.226

7.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

8.  Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States.

Authors:  Manish Patel; Jufu Chen; Sara Kim; Shikha Garg; Brendan Flannery; Zaid Haddadin; Danielle Rankin; Natasha Halasa; H Keipp Talbot; Carrie Reed
Journal:  Emerg Infect Dis       Date:  2020-04-29       Impact factor: 6.883

9.  Power for tests of interaction: effect of raising the Type I error rate.

Authors:  Stephen W Marshall
Journal:  Epidemiol Perspect Innov       Date:  2007-06-19

10.  Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study.

Authors:  Casey P Durand
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more
  5 in total

1.  The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia.

Authors:  Liang Chen; Xiudi Han; YanLi Li; Chunxiao Zhang; Xiqian Xing
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-08-24       Impact factor: 3.944

2.  Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.

Authors:  Peter J Embi; Matthew E Levy; Allison L Naleway; Palak Patel; Manjusha Gaglani; Karthik Natarajan; Kristin Dascomb; Toan C Ong; Nicola P Klein; I-Chia Liao; Shaun J Grannis; Jungmi Han; Edward Stenehjem; Margaret M Dunne; Ned Lewis; Stephanie A Irving; Suchitra Rao; Charlene McEvoy; Catherine H Bozio; Kempapura Murthy; Brian E Dixon; Nancy Grisel; Duck-Hye Yang; Kristin Goddard; Anupam B Kharbanda; Sue Reynolds; Chandni Raiyani; William F Fadel; Julie Arndorfer; Elizabeth A Rowley; Bruce Fireman; Jill Ferdinands; Nimish R Valvi; Sarah W Ball; Ousseny Zerbo; Eric P Griggs; Patrick K Mitchell; Rachael M Porter; Salome A Kiduko; Lenee Blanton; Yan Zhuang; Andrea Steffens; Sarah E Reese; Natalie Olson; Jeremiah Williams; Monica Dickerson; Meredith McMorrow; Stephanie J Schrag; Jennifer R Verani; Alicia M Fry; Eduardo Azziz-Baumgartner; Michelle A Barron; Mark G Thompson; Malini B DeSilva
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-11-05       Impact factor: 17.586

3.  Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies.

Authors:  Nozomi Takahashi; Xavier Saelens; Peter Vandenabeele; Teodora Oltean; Lorena Itati Ibanez; Tatyana Divert; Tine Ysenbaert; Hannelore Van Eeckhoutte; Vera Goossens; Michael Schotsaert; Ken Bracke; Bert Schepens; Jonathan Maelfait
Journal:  Cell Death Dis       Date:  2022-03-29       Impact factor: 9.685

4.  Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice.

Authors:  Yue Du; Shengnan Zhang; Zhaoyong Zhang; Kamran M Miah; Peilan Wei; Lu Zhang; Yuhui Zhu; Zhengtu Li; Feng Ye; Deborah R Gill; Stephen C Hyde; Yanqun Wang; Jincun Zhao
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

5.  Stably Integrating an Inducible CRISPR-Cas9 to Protect Against Viral Infections in Vitro.

Authors:  Indeever Madireddy; Merrick Pierson Smela
Journal:  MicroPubl Biol       Date:  2022-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.